AMRN - Amarin Corporation plc

NasdaqGM - NasdaqGM Real-time price. Currency in USD
16.29
-0.40 (-2.40%)
As of 1:50PM EST. Market open.
Stock chart is not supported by your current browser
Previous close16.69
Open16.46
Bid16.27 x 1100
Ask16.28 x 1100
Day's range16.14 - 16.74
52-week range2.35 - 23.34
Volume1,979,265
Avg. volume18,551,082
Market cap5.26B
Beta (3Y monthly)-0.13
PE ratio (TTM)N/A
EPS (TTM)-0.37
Earnings date4 May 2017 - 8 May 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est34.80
Trade prices are not sourced from all markets
  • Here's Why Amarin Fell 13.6% in November
    Motley Fool4 days ago

    Here's Why Amarin Fell 13.6% in November

    New clinical data gave investors pause, while management wisely took advantage of the soaring stock price to raise capital through a share offering.

  • Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
    Zacks11 days ago

    Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

    Amarin (AMRN) closed at $17.67 in the latest trading session, marking a -1.83% move from the prior day.

  • 2 Biotech Stocks Poised for Big Gains in 2019
    Motley Fool11 days ago

    2 Biotech Stocks Poised for Big Gains in 2019

    Amarin and Novavax could crush the broader markets in 2019. Here's why.

  • GlobeNewswire16 days ago

    Market Trends Toward New Normal in Amarin, BioSpecifics Technologies, Cavco Industries, Iconix Brand Group, A-Mark Precious Metals, and Core-Mark Holding — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Why U.S. Steel, Amarin, and Papa John's International Slumped Today
    Motley Fool17 days ago

    Why U.S. Steel, Amarin, and Papa John's International Slumped Today

    Find out why these stocks missed out on an afternoon market rebound.

  • Why Amarin's Latest News Caused Shares to Crash 13% Today
    Motley Fool17 days ago

    Why Amarin's Latest News Caused Shares to Crash 13% Today

    The company's diluting existing shareholders to finance expenses ahead of an expected increase in demand.

  • GlobeNewswire18 days ago

    Amarin Prices Public Offering of American Depositary Shares

    Amarin Corporation plc (AMRN) today announced the pricing of the underwritten public offering of its American Depositary Shares ("ADSs") for gross proceeds of approximately $200.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Amarin. In addition, Amarin has granted the underwriters a 30-day option to purchase approximately $30.0 million of additional ADSs. Jefferies and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering.

  • GlobeNewswire18 days ago

    Amarin Announces Proposed Public Offering of American Depositary Shares

    Amarin Corporation plc (AMRN) today announced a registered underwritten public offering of its American Depositary Shares (“ADSs”).  All of the shares in the proposed offering are to be sold by Amarin.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Jefferies and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering.

  • A Look at Amarin Corporation’s Stock Performance Year-to-Date
    Market Realist18 days ago

    A Look at Amarin Corporation’s Stock Performance Year-to-Date

    Amarin stock rose from $2.35 at the close of market on December 29, 2017, to $18.97 at the close of market on November 21, 2018, reflecting a ~449% year-to-date rise. Amarin hit its 52-week high of $23.34 on November 6. Amarin’s net revenue in the first nine months of 2018 amounted to $151.9 million compared to $127.2 million in the same period of the previous year, reflecting a ~19% YoY (year-over-year) rise.

  • GlobeNewswire24 days ago

    Amarin to Present at the Evercore ISI HealthCONx Conference

    BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 20, 2018 -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of.

  • Amarin Corporation plc (NASDAQ:AMRN) Is Expected To Breakeven
    Simply Wall St.28 days ago

    Amarin Corporation plc (NASDAQ:AMRN) Is Expected To Breakeven

    Amarin Corporation plc’s (NASDAQ:AMRN): Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company’s Read More...

  • Why Amarin Corporation's Stock Is on the Mend Today
    Motley Fool29 days ago

    Why Amarin Corporation's Stock Is on the Mend Today

    Amarin's business update at an investor conference helped to calm investors' nerves today.

  • How Has Amarin Performed in 2018?
    Market Realist29 days ago

    How Has Amarin Performed in 2018?

    In the first nine months of 2018, Amarin reported revenues of $151.3 million, which is 20.0% YoY growth. Analysts expect Amarin to report a gross margin of 75.43% in 2018, which will be a rise of 25 basis points YoY. The company is expected to witness a gross margin of 76.67% in 2019, which will be an improvement by 123 basis points YoY.

  • Why Is Amarin Corporation Stock Up 300% in 2018?
    Motley Fool29 days ago

    Why Is Amarin Corporation Stock Up 300% in 2018?

    Amarin's breakthrough in the cardiovascular care setting sent its shares soaring this year.

  • What to Expect from Amarin’s Expenses in 2018
    Market Realist29 days ago

    What to Expect from Amarin’s Expenses in 2018

    Currently, Amarin (AMRN) is focused on creating awareness for Vascepa across new territories. According to Amarin’s third-quarter earnings conference call, the company is initially targeting territories that have the potential to become profitable in a short timeframe. Amarin has been targeting ~20,000 general practitioners to increase Vascepa’s adoption. General practitioners are the first physicians that patients visit when they’re suffering from high cardiovascular risk. General practitioners account for almost 85% of the total physicians that Amarin is targeting. Among the remaining physicians, ~7% are cardiologists and 5% are endocrinologists.

  • What Are Amarin’s Earnings Projections for 2018?
    Market Realistlast month

    What Are Amarin’s Earnings Projections for 2018?

    According to Amarin’s (AMRN) third-quarter earnings conference call, the company secured prescription approval rates of 75% for Vascepa from Managed Care organizations—similar to the approval rates witnessed by generic Lovaza. The company has been witnessing rapid revenue growth for Vascepa, despite a narrow label and low salesforce. Amarin is focused on capacity expansion, which could support more than $1.0 billion worth of Vascepa’s net revenues in 2019.

  • Amarin’s Revenue Projections for 2018
    Market Realistlast month

    Amarin’s Revenue Projections for 2018

    In the third-quarter earnings conference call, Amarin (AMRN) didn’t provide any revenue guidance for the fourth quarter, 2018, or 2019. After the REDUCE-IT trial results, Amarin aims to increase the number of sales representatives in the US market to 400 by the beginning of 2019. According to Amarin’s third-quarter earnings conference call, the expanded sales force and primary results published in the American Heart Association presentation on November 10 are expected to drive Vascepa’s revenue growth in future quarters.

  • Analyzing Amarin’s Stock Price Movements in November
    Market Realistlast month

    Analyzing Amarin’s Stock Price Movements in November

    On November 12, Amarin (AMRN) stock closed at $19.82, which is 5.84% lower than its previous closing price. On November 10, Amarin issued a press release announcing favorable primary results from the cardiovascular outcomes trial—REDUCE-IT. Despite the favorable outcomes from REDUCE-IT, the stock has been impacted negatively due to queries raised by researchers and cardiologists about the use of mineral oil as a placebo in the cardiovascular outcomes trial.

  • Why Halliburton, Tyson Foods, and Amarin Slumped Today
    Motley Foollast month

    Why Halliburton, Tyson Foods, and Amarin Slumped Today

    Bad news on multiple fronts hit these stocks hard.

  • Here's Why Amarin Corporation Tumbled 20% Today
    Motley Foollast month

    Here's Why Amarin Corporation Tumbled 20% Today

    Questions about its high-profile cardiovascular trial data are making investors more cautious.

  • Amarin's Vascepa Cuts Heart Risk in Outcomes Test, Stock Down
    Zackslast month

    Amarin's Vascepa Cuts Heart Risk in Outcomes Test, Stock Down

    Amarin (AMRN) posts detailed data from a late-stage cardiovascular outcomes study on its fish oil drug Vascepa. The stock takes a hit.

  • Why Amarin Corporation's Stock Is Falling Today
    Motley Foollast month

    Why Amarin Corporation's Stock Is Falling Today

    Amarin's lead drug lost some of its luster after a conference presentation over the weekend.

  • Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
    Zackslast month

    Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?

    Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.